Thermalin is engineering new forms of insulin that will lower the burden of insulin use, increase patient adoption of and adherence to insulin therapy, improve patient lives and outcomes, and lower the cost of caring for people with Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D).
Founded in 2010 based on pioneering work by Dr. Michael Weiss on the structure and function of insulin analogues, Thermalin is overcoming the limitations of existing insulin products by re-engineering the insulin molecule to be more stable and to act more selectively. Thermalin’s formulations of these new molecules enable new delivery devices and systems that will transform lives.  On September 28, Thermalin announced a worldwide collaboration with Sanofi on two of its insulin programs as well as a $17.5M Series A Financing that is being led by Sanofi.

Open Positions

Research Associate – Protein Formulation

Cleveland, OH

Are you passionate about improving diabetes treatment?  Are you meticulous in your work?  Are you an innovative, team player?  If so, then you will want to contact us!  Thermalin is looking for a Research Associate – Protein Formulation to join our team.   In this role, you will formulate insulin analogs for preclinical development Research Associate Responsibilities: Formulate novel insulin analogs using established pro ...

Learn more

Laboratory Associate – Bioconjugation

Cleveland, OH

Laboratory Associate – Bioconjugation Are you passionate about improving diabetes treatment?  Are you meticulous in your work?  Are you an innovative, team player?  If so, then you will want to contact us!  Thermalin is looking for a Laboratory Associate – Bioconjugation to join our team.   In this role, you will Perform peptide/protein covalent modifications and bioconjugation to support project goals.     ...

Learn more

Lab Associate- Bioassays

Cleveland, OH

Company Background Thermalin Inc. is developing a pipeline of patent pending insulin analogs that address significant unmet needs in the rapidly growing insulin market ($17B today, $70B expected worldwide by 2030).  Founded on a portfolio of new insulin analogs invented by Dr. Michael Weiss, Chairman Emeritus of Biochemistry at Case Western Reserve Medical School and Director of Therapeutic Protein Institute, Thermal ...

Learn more